

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

A)



B)

VH primers:

a DP47baNco GCG GCC CAG CAT GCC ATG GCC GAG GTG CAG CTG TTG GAG TCT GGG  
 CDR3for GGT TCC CTG GCC CCA GTA GTC AAA MNN MNN MNN MNN TTT CGC ACA GTA  
 ATA TAC G  
 c VHpullth GCG GCC CAG CAT GCC ATG GCC GAG  
 d Jassm CCC GCT ACC GCC ACT GGA CCC ATC GCC ACT CGA GAC GGT GAC CAG GGT  
 TCC CTG GCC CCA GTA GTC

VL primers:

e DPK22assm GAT GGG TCC AGT GGC GGT AGC GGC GGG GGC GCG TCG ACT GGC GAA ATT GTG  
 TTG ACG CAG TCT CC  
 f DPK3for CAC CTT GGT CCC TTG GCC GAA CGT MNN CGG MNN MNN ACC MNN CTG CTG  
 ACA GTA ATA CAC TGC  
 g Jfornot GAG TCA TTC TCG ACT TGC GGC CGC TTT GAT TTC CAC CTT GGT CCC TTG GCC  
 GAA CG  
 h pullth GAT GGG TCC AGT GGC GGT AGC GGG

Figure 1




Figure 2A




Figure 2B



Figure 3





Figure 4



time (h)	scFv (L19)							scFv (D1.3)	
	Kidney	Spleen	Lung	Liver	Brain	Blood	Tumor	Blood	Tumor
0.25	26.4 ± 4.7	5.4 ± 0.4	15.1 ± 5.1	5.7 ± 0.6	0.4 ± 0.04	14.4 ± 2.6	4.6 ± 1.0	12.7 ± 0.1	4.4 ± 0.4
1	19.2 ± 3.9	3.8 ± 0.3	9.8 ± 0.9	2.8 ± 0.3	0.3 ± 0.1	8.3 ± 0.9	6.9 ± 2.4	5.7 ± 0.7	3.6 ± 1.0
3	8.1 ± 1.6	2.0 ± 0.3	5.0 ± 1.4	1.7 ± 0.02	0.2 ± 0.01	4.3 ± 0.3	8.2 ± 4.2	—	—
5	4.2 ± 1.1	1.8 ± 0.2	3.5 ± 0.2	1.3 ± 0.3	0.1 ± 0.02	2.0 ± 1.6	7.7 ± 2.5	4.6 ± 1.2	2.6 ± 1.5
24	0.7 ± 0.1	0.4 ± 0.1	1.0 ± 0.1	0.2 ± 0.04	0.02 ± 0.01	0.4 ± 0.1	4.7 ± 0.6	1.1 ± 0.5	0.7 ± 0.4

Figure 5

VH

E V Q L L E S G G G	L V Q P G G S L R L	S C A A S G F T F S
S F S M S W V R Q A	P G K G L E W V S S	I S G S S G T T Y Y
A D S V K G R F T I	S R D N S K N T L Y	L Q M N S L R A E D
T A V Y Y C A K P F	P Y F D Y W G Q G T	L V T V S S


linker

G D G S S G G S G G A S T G

VL

E I V L T Q S P G T	L S L S P G E R A T	L S C R A S Q S V S
S S Y L A W Y Q Q K	P G Q A P R L L I Y	Y A S S R A T G I P
D R F S G S G S G T	D F T L T I S R L E	P E D F A V Y Y C Q
Q T G R I P P T F G	Q G T K V E I K	

Figure 6: Amino acid sequence of antibody L19



day 9 / rabbit 1 / left / nC



day 9 / rabbit 1 / right / VEGF high



day 9 / rabbit 2 / left / PMA



day 9 / rabbit 2 / left / VEGF low



day 9 / rabbit 3 / left / VEGF high



day 9 / rabbit 3 / right / PMA



day 9 / rabbit 4 / left / PMA



day 9 / rabbit 4 / right / nC

Figure 7




Figure 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12

FIGURE 13





FIGURE 14





FIGURE 15

# Radioimmunotherapy with anti-angiogenesis antibodies



vessels = 0.5 - 5%  
of total tumour mass






FIGURE 16



<sup>1</sup>H-NMR spectrum of 3-(trimethylstannyl)-benzoic acid in CDCl<sub>3</sub>

FIGURE 17a





FIGURE 17b

$^1\text{H-NMR}$  spectrum of 3-(trimethylstannyl)-benzoic acid in  $\text{CDCl}_3$



Current Data Parameters  
 NAME tcst\_0004  
 EXPNO 1  
 PROBNO

F2 - Acquisition Parameters

Date 990804  
 1.1mc 11.19  
 INSTRUM drx600  
 PROBID 5 mm TXI 13C  
 PULPROG zgpr-eth  
 TD 8192  
 SOLVENT CDCl3  
 NS 16  
 DS 2  
 SWH 9615.385 Hz  
 FIDRES 1.173753 Hz  
 A0 0.4260340 sec  
 RG 800  
 DW 52.000 usec  
 DE 8.00 usec  
 TE 294.0 K  
 D1 1.0000000 sec

..... CHANNEL 11 .....

NUC1  $^1\text{H}$   
 P1 8.00 usec  
 PL1 0.00 dB  
 PG9 120.00 dB  
 SFO1 600.1328114 MHz

..... GRADIENT CHANNEL .....

GPNAME1 sine 32  
 GPX1 0.00 %  
 GPY1 0.00 %  
 GPZ1 50.00 %  
 P21 1000.00 usec

F2 - Processing parameters

SI 4096  
 SF 600.1300239 MHz  
 MDW 0.00 Hz  
 S90 3  
 LB 0.00 Hz  
 GB 0  
 PC 1.00

10 NMR plot parameters  
 CX 20.00 cm  
 F1P 8.513 ppm  
 F1 5108.78 Hz  
 F2P 6.977 ppm  
 F2 4167.17 Hz  
 PRDCH 0.07678 ppm/cm






FIGURE 18a

$^1\text{H-NMR}$  spectrum of N-succinimidyl-3-(trimethylstanny)-benzoate in  $\text{CDCl}_3$



$(\text{CH}_3)_3$

m-MeATE



ppm

FIGURE 18b

$^1\text{H}$ -NMR spectrum of N-succinimidyl-3-(trimethylstannylyl)-benzoate in  $\text{CDCl}_3$




FIGURE 19

EI-MS of N-succinimidyl-3-(trimethylstannyl)-benzoate in CDCl<sub>3</sub>

